Key result
Aspirin for primary prevention provides a marginal reduction in nonfatal cardiovascular events that is largely offset by increased bleeding risk, limiting its routine use to selected patients.
Why the study?
Does aspirin prevent major cardiovascular events in patients without established cardiovascular disease?
Does aspirin prevent major cardiovascular events in patients without established cardiovascular disease?
Routine use of aspirin for primary prevention is discouraged in healthy elderly and low-risk patients due to bleeding risks outweighing marginal cardiovascular benefits, though it may be considered in select higher-risk patients.
Supports limited aspirin primary prevention per guidelines; leaves open dedicated trials in higher-risk patients.
Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.
No takes yet. Share an insight, caveat, or question.
Schenone et al. (2020) conducted a review in Atherosclerotic cardiovascular disease. Aspirin vs. Placebo or no aspirin was evaluated. Aspirin for primary prevention provides a marginal reduction in nonfatal cardiovascular events that is largely offset by increased bleeding risk, limiting its routine use to selected patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: